Check Your Claims Before Reviewers Do

 Quick Explanation Copied

 Long Explanation

Career-scale evidence

Marc Steffen Raab (German Cancer Research Center / Heidelberg University; ORCID 0000-0003-4181-6922) has an OpenAlex record of 643 works, ~12,996 citations and h-index 56 — but at least three unmerged secondary profiles exist (e.g., "Marc-Steffen Raab": 91 works, 2,467 citations, h 23), so true bibliometric totals are higher than any single profile shows. OpenAlex bibliometric profile (h-index 56) Output accelerated from ~5–9 works/year (2004–2014) to 26–33/year (2016–2022) and a 182-work spike in 2023 — a pattern typical of consortium/trial authorship rather than a lone-author burst.

His most-cited work spans the full translational arc: a first-authored Lancet seminar on myeloma (697 citations) Lancet myeloma seminar (2009, first author), co-authorship on the NEJM selinexor trial in triple-class refractory disease NEJM selinexor trial (2019), and the 2023 Nature Medicine MagnetisMM-3 elranatamab phase 2 (651 citations). Nature Medicine elranatamab phase 2 (2023) He also co-authors disease-biology genomics, e.g., the Blood study mapping myeloma oncogene dependencies onto primary cytogenetic events (473 citations). Blood myeloma mutational drivers study (2018)

Split-flow (2026): the methods contribution

The deepest-dive paper reframes disagreement between hashing-based (HTODemux, MultiSeqDemux) and SNP-based (Souporcell, Vireo) demultiplexers as a structured cell-quality signal, not noise, and ships an open-source Nextflow pipeline. Split-flow demultiplexing preprint (2026) Reported validation across 14 MM donors and AML snMultiome/scRNA/scATAC pools: consensus singlet fraction of only 0.374 at full depth (0.565 with relaxed Vireo-WGS settings); lenient filtering retains 42,970 T cells at 87.1% purity (derived: 100 − 12.9% cross-donor contamination) versus 34,756 cells at 99.2% purity for high-confidence Split-flow, plus 5.3-fold enrichment of VDJdb-confirmed public TCRs. Declared limitations: heuristic thresholds, incomplete genotype ground truth, a fixed toolset, and hematology-only testing. Funding is public (DFG, BMBF, EU) with no competing interests declared — a strong posture for methods work.

European practice patterns (2016): the industry-facing genre

A second deep-dive paper shows a different mode: an Amgen-funded observational chart review (435 physicians; 7,635 cross-sectional plus 4,997 retrospective charts; 7 countries) reporting first-line bortezomib 48%, lenalidomide second-line 60% and first-line maintenance 45%, and SCT receipt 31% against 44% eligibility. European myeloma practice chart review (2016) It is useful real-world evidence, but with disclosed sponsor funding, no multiple-comparison adjustment, and acknowledged selection toward SCT-capable centers — a genre contrast with the independently funded, code-released 2026 work.

Blind spots and what would change the verdict

• Bibliometric blur: fragmented OpenAlex profiles and consortium-heavy middle authorship make per-paper credit attribution imprecise.
• Preprint status: the flagship 2026 contribution is unreviewed (May 2026); the 0.374 full-depth consensus singlet fraction is striking and needs external replication before adoption.
• Sponsor exposure: Amgen funding on descriptive epidemiology is disclosed but is a structural sponsor-bias channel.

The assessment would weaken if Split-flow's purity/TCR enrichment fails replication on non-hematologic tissues, or if concordance tiers merely proxy sequencing depth rather than cell quality; it would strengthen with a merged profile confirming robust first/senior authorship fractions. Merged Bibliometric Audit Conflict-of-Interest Analysis

 BGPT Author Review

Scientific Quality

A sustained, high-impact myeloma program: first-authored Lancet seminar, co-authorship on landmark NEJM/Nature Medicine trials and genomic stratification studies, plus a credible recent entry into computational methods (Split-flow) with open-source code and orthogonal TCR validation. Capped below 9–10 because much output is consortium middle-authorship, the flagship 2026 contribution is an unreviewed preprint with heuristic thresholds, and part of the portfolio is industry-funded descriptive work; OpenAlex profile fragmentation also blurs precise credit attribution.

Communication Quality

The Split-flow preprint is well structured — a clear five-category framework, declared falsification criteria, an open GitHub pipeline, and transparent limitations; the chart review is readable descriptive epidemiology. Judged only from two texts plus metadata, with no visible pedagogical or public-facing communication record, and key quantities (singlet fractions, purity) demand careful reading.

Author Novelty

The trial and genomic work extends established myeloma paradigms rather than overturning them. The genuinely novel element is reframing inter-method demultiplexing discordance as an information-bearing quality gradient and productizing it as an open pipeline; the remainder is competent but incremental within a crowded field.

Scientific Rigor

Strengths: orthogonal TCR/VDJdb validation, cross-donor contamination quantification, multi-dataset generalization, public funding, declared absence of competing interests in the 2026 work. Weaknesses: heuristic concordance thresholds not formally optimized, incomplete donor genotype ground truth, a limited toolset benchmark, no multiple-comparison adjustment plus disclosed Amgen sponsorship with selection bias in the 2016 chart review, and preprint status for the flagship paper.